Unicycive Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page hereto)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Shalabh Gupta as his or her attorney-in-fact, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Shalabh Gupta | Chief Executive Officer, President and Chairman of the Board of Directors | March 30, 2026 |
| Shalabh Gupta | (Principal Executive Officer) | |
| /s/ John Townsend | Chief Financial Officer | March 30, 2026 |
| John Townsend | (Principal Financial and Accounting Officer) | |
| /s/ Sandeep Laumas, M.D. | Director | March 30, 2026 |
| Sandeep Laumas, M.D. | ||
| /s/ Saraswati Kenkare-Mitra, Ph.D. | Director | March 30, 2026 |
| Saraswati Kenkare-Mitra, Ph.D. | ||
| /s/ Gaurav Aggarwal, M.D. | Director | March 30, 2026 |
| Gaurav Aggarwal, M.D. | ||
-85-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.